Grifols (Grifols) Institutional Ownership : 0.03% (As of Apr. 25, 2024)

View and export this data going back to 2008. Start your Free Trial

What is Grifols Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Grifols's institutional ownership is 0.03%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Grifols's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Grifols's Float Percentage Of Total Shares Outstanding is 0.00%.

Grifols Institutional Ownership Historical Data

The historical data trend for Grifols's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Institutional Ownership Chart

Grifols Historical Data

The historical data trend for Grifols can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03

Grifols Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (OTCPK:GIKLY) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

GIFOF:USA GIFLF:USA GRFS:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain OZTA:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.